Pathstone Holdings
MDGL icon

Pathstone Holdings’s Madrigal Pharmaceuticals MDGL Stock Holding History

Pathstone Holdings’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.81M Sell
5,233
-224
-4% -$115K 0.01% 924
2026
Q1 		$2.86M Buy
5,457
+724
+15% +$346K 0.01% 843
2025
Q4 		$2.76M Buy
4,733
+2,297
+94% +$1.17M 0.01% 861
2025
Q3 		$1.12M Buy
+2,436
New +$909K ﹤0.01% 1352

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Pathstone Holdings's MDGL Position: Q2 2026 in Review

Pathstone Holdings reduced its Madrigal Pharmaceuticals (MDGL) stake by 4.1% in Q2 2026, selling an estimated $115K and leaving 5,233 shares worth $2.81M. The position accounts for 0.01% of the portfolio, ranked #924.

Pathstone Holdings first reported a position in MDGL in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.86M in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Pathstone Holdings held 5,233 shares of Madrigal Pharmaceuticals worth $2.81M as of Q2 2026.
  • Pathstone Holdings sold 224 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $115K.
  • Madrigal Pharmaceuticals made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #924 holding.
  • Pathstone Holdings first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Pathstone Holdings's Madrigal Pharmaceuticals position peaked at $2.86M in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.